These data suggest a scenario of combined CTX action by direct blockage of adrenocortical tumor progression and indirect suppression of LH and steroid hormone concentrations that could be used for the benefit of the patient. This evidence concerns the gene PLOD1 and adrenal cortex neoplasm.